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PPARc activators inhibit cancer cell growth. However the role of these agents in progression/metastasis is not well-defined.
Using an orthotopic model of lung cancer, we showed that pioglitazone accelerated progression/metastasis through affects
on macrophages. This suggests that potential therapeutic agents may have opposing effects on cancer in different cells.
For most cancers, including lung cancer,
patient survival is more closely linked to
metastasis than primary tumor burden,
underscoring the need to develop inhibitors
of metastasis. A critical difference between
tumor initiation and progression/metastasis
is the role of the tumor microenvironment
(TME). Cancer initiation in solid tumors
largely involves changes in epithelial cells,
whereas progression/metastasis depends on
interactions between cancer cells and the
surrounding stroma. Thus when targeting
a specific molecular pathway, a potential
complication is that the particular pathway
may have opposing physiologic effects in
different cell types. This has been demon-
strated in the case of NFkB and hepato-
cellular carcinoma. Work from the Karin
lab showed that activation of NFkBi n
hepatocytes protects against cancer deve-
lopment, whereas activation of the same
pathway in myeloid lineages (Kupffer cells)
promotes cancer progression.
1 Activation of
the nuclear receptor peroxisome prolifera-
tor-activated receptor-c (PPARc) has been
extensively studied in numerous cancers.
This nuclear receptor is the target for the
thiazolidinediones class of agents (TZDs),
including rosiglitazone and pioglitazone.
S t u d i e si nc e l ll i n e sa n da n i m a lm o d e l sh a v e
demonstrated inhibition of tumor growth
and promotion of a more differentiated, less
invasive phenotype. In lung cancer interest
in these agents was increased by a retro-
spective study showing decreased incidence
of lung cancer in patients using TZDs to
treat diabetes.
2 Our laboratory has studied
effects of PPARc activation in human non-
small cell lung cancer cells (NSCLC), and
shown inhibition of transformed growth
and invasiveness.
3 We therefore sought to
determine the effects of these agents on
lung cancer progression. We used a recently
developed orthotopic model in which
murine lung cancercellsare injecteddirectly
into the left lobe of the lung of immuno-
competent mice. These cells form tumors
which progress to secondary pulmonary
tumors and metastasize to the liver and
brain. Our expectation was that TZDs
would inhibit tumor progression in this
model. Unexpectedly, we have found that
administration of pioglitazone increased the
rate of progression and the number of liver
and brain metastasis.
4 In light of anti-
tumorigenic effects on these cancer cells in
vitro, we hypothesized that the pro-meta-
static effects of pioglitazone were mediated
through effects on the TME.
Macrophages play a critical role in
cancer progression. A model has been
proposed in which macrophages undergo a
phenotypic modulation in the setting of
tumors from a pro-inflammatory pheno-
type designated M1 to an alternatively
activated phenotype designated M2.
5 M2
macrophages promote tumor progression
through production of pro-angiogenic
cytokines. In light of studies demonstrat-
ing promotion of the M2 phenotype by
TZDs in the setting of atherosclerosis,
6
we focused on macrophages. Tissues
from pioglitazone-treated mice showed
increased numbers of M2 macrophages.
In mice with targeted deletion of PPARc
in myeloid lineages, we found marked
inhibition of tumor progression and
metastasis, and this was associated with
decreased numbers of M2 macrophages.
Based on these findings we propose that
activation of PPARc plays a dual and
opposing role in cancer. In cancer cells it
inhibits proliferation and promotes differ-
entiation, whereas in macrophages in
promotes progression by mediating con-
version of these cells to an alternatively
activated phenotype. The relevance of
these findings is underscored by several
studies that have demonstrated an associa-
tion of increased number of M2 macro-
phages in human lung tumors with worse
outcomes.
7 Thus the potential efficacy of
pioglitazone will depend on which cell
type is playing a dominant role. In the
setting of chemoprevention, the major
target appears to be the lung epithelial cell,
whereas during progression and metastasis
the TME plays an increasingly important
role. Our findings suggest that care needs to
be taken in going forward with this class of
agents, and underscores the need to be
careful in extrapolating findings in chemo-
prevention to a therapeutic setting.
Several important questions remain
unanswered. First, the pathways whereby
alternatively activated macrophages pro-
mote progression of lung cancer are not
well understood. Additional studies are
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2required todefineatwhatstageofmetastasis
these cells are important. In breast cancer,
work by Condeelis and coworkers has
defined a role for macrophages in multiple
stages of metastasis.
8 Analogous studies need
to be performed in lung cancer. These
studies suggest that selective activators of
PPARc may represent novel therapeutic
agents. In collaboration with Dr. Robert
Winn we have demonstrated that the
prostacyclin analog iloprost can activate
PPARc in human NSCLC, but that this is
dependent on expression of the Wnt
canonical receptor Frizzled 9.
9 Thus iloprost
represents a potential targeted activator of
PPARc which will only act on Frizzled
9-positive cells. It is currently not known
whether macrophages express this protein;
however, it these cells lack Frizzled 9, it
would be predicted that iloprost may repre-
sent a targeted activator of PPARc with
potential therapeutic efficacy (see Fig.1).
Finally, an additional implication of this
study relates to the role of inflammation
and cancer progression. Our studies
demonstrate that promotion of and alter-
natively activated macrophage, which is
associated with the anti-inflammatory
effects of pioglitazone in vascular disease
actually promotes tumor progression.
Analogous findings with other anti-inflam-
matory pathways are beginning to emerge.
For example, activation of the purinergic
pathway which inhibits colitis, in fact
promotes colon cancer metastasis.
10 Thus a
deeper understanding of the nature of
pro and anti-inflammatory pathways is
required to develop new therapeutics
targeting cancer progression.
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Figure1. Activators of PPARc have opposing effects on tumor progression in different cell types. In transformed epithelial cells or full-fledged cancer
cells, this pathway is growth inhibitory. In contrast, in macrophages, these agents promote the alternatively activated (M2 phenotype), which promotes
cancer progression through mechanisms which are not completely understood. The net response to an agent such as pioglitazone will depend on
the balance between effects on different cell types. Prostacyclin analogs such as iloprost also activate PPARc, but require expression of Frizzled 9 (Fzd9)
on the target cells. This raises the possibility that these agents may represent targeted activators of PPARc, and potential novel therapeutics.
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